Loading
Bastide le Confort Medical Stock: price and insider trades · France
No insider purchase over the last 90 days. The latest was filed 13 May 2025.
Bastide le Confort Medical: what insiders have been doing
This page follows insider dealings at Bastide le Confort Medical as filed with AMF, a company from the Healthcare & Pharma sector. Bastide le Confort Medical has had no insider filing for more than a year; the last one goes back to 13 May 2025.
The full history, which starts in 2021, counts 9 purchases against no sales.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. This summary is built from AMF disclosures alone and does not predict where the share price will go.
Insider Decl.
11
Thresholds
n/a
Buy Volume
€291,518
9 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleVincent BASTIDE5 buys
Since the insiders bought
- +0.2%Entry €27.30 · Close at T+365 €27.35
- -31.3%Entry €48.60 · Close at T+365 €33.40
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Fundamental score
Ranked 7,435 of 24,148 companies
61.2
score / 100
Value72
Quality51
FCF yld27%
Earn yld0.3%
EV/EBITDA5.5x
ROE12%
Gross mgn68%
Net mgn0.1%
Debt/EBITDA4.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended June 2025 · cache
€21.00
Analyst consensus
1 analysts1.00/5
€31.00Target €31.00(+48%)€31.00
Income statement
Revenue€491.2M
Gross profit€333.0M68% margin
EBITDA€102.0M21% margin
Net income€528k5.8% margin
Valuation
PER (trailing)26.9x
PER (forward)12.2x
P/Book1.5x
Beta0.90
Balance sheet & cash
Market cap€153.5M
Total debt€411.2M
Free Cash Flow€41.7M
Debt / Equity316%
Profitability & ownership
ROE11.6%
ROA4.8%
% insiders55.8%
% institutions13.7%
Last declaration on 13 May 2025
Declarations11 total
978 shares@ €25.675313.0% of flowActionEuronext ParisISIN FR00000353702025DD1032136
Canonical exit: 10 Jul 2025 (T+90)
1,084 shares@ €25.468414.2% of flowActionEuronext ParisISIN FR00000353702025DD1031174
Canonical exit: 7 Jul 2025 (T+90)
1,900 shares@ €25.212524.7% of flowActionEuronext ParisISIN FR00000353702025DD1030740
Canonical exit: 3 Jul 2025 (T+90)
904 shares@ €27.446212.8% of flowActionEuronext ParisISIN FR00000353702025DD1029941
Canonical exit: 1 Jul 2025 (T+90)
914 shares@ €27.547913.0% of flowActionEuronext ParisISIN FR00000353702025DD1027990
Canonical exit: 23 Jun 2025 (T+90)
3,000 shares@ €14.4222.3% of flowActionEuronext ParisISIN FR00000353702024DD960632
Canonical exit: 8 Jul 2024 (T+90)
100,000 shares0ActionEuronext ParisISIN FR00000353702023DD919944
700 shares@ €47.412934.0% of flowActionEuronext ParisISIN FR00000353702022DD816734
Canonical exit: 14 Apr 2022 (T+90)
367 shares@ €47.6817.9% of flowActionEuronext ParisISIN FR00000353702022DD816740
Canonical exit: 13 Apr 2022 (T+90)
933 shares@ €50.330248.1% of flowActionEuronext ParisISIN FR00000353702022DD816699
Canonical exit: 17 Apr 2022 (T+90)
00ActionHors plateforme de négociationISIN FR00000353702021DD757635
11 of 11 declarations
About Bastide le Confort Medical
Bastide Le Confort Médical is a leading French home healthcare provider and medical-device distributor listed on Euronext Paris under ISIN FR0000035370. The company was founded in 1977 in Nîmes by Guy Bastide, a pharmacist who built the business around a simple but powerful idea: patients should be able to receive high-quality care at home, with a level of support comparable to hospital-based treatment. That founding principle remains central to the group’s identity and long-term strategy.
Originally focused on respiratory care, Bastide gradually broadened its service portfolio to become a comprehensive homecare platform. Today, the group operates across six core therapeutic areas: diabetes, nutrition, infusion, respiratory care, stoma care and urology, wound healing, and broader home support services. Its model combines medical devices, care protocols, monitoring, maintenance, and patient support, with an emphasis on continuity of care and close coordination with healthcare professionals. Bastide positions itself as a partner that helps improve patient comfort, autonomy, and quality of life.
Read moreShow less
From a market standpoint, Bastide holds a strong position in France, particularly in respiratory homecare and device-based support services, where it is described by the company as one of the French leaders. The group has also built a broad territorial footprint through a network of agencies, integrated stores, and franchises. According to its latest disclosures, Bastide operates 110 franchises and 54 integrated stores in France, enabling it to combine local proximity with operational consistency. Internationally, the group reports a presence in 8 countries across 3 continents, reflecting a strategy of selective geographic expansion.
Recent financial performance confirms the resilience of the model. In fiscal year 2024-2025, continuing operations generated revenue of €491.2 million, up 8% year on year, while recurring operating margin reached 9.0% and operating free cash flow amounted to €23.3 million. As of December 31, 2025, Bastide reported leverage of 2.77x, improving versus 3.41x at June 30, 2025, which underscores a steady deleveraging trend after portfolio simplification and asset disposals.
On governance, Bastide Le Confort Médical is a French public limited company with a board of directors, led by Vincent Bastide. The group also highlights CSR as a core pillar of its corporate purpose, consistent with its exposure to structural healthcare needs driven by population aging, chronic diseases, and the expansion of care at home.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
